coronavirus, Covid-19, Ein Kerem, Hadassah Hospital, Hadassah Medical Centre, Hadassah UK, innovation, Israel, Jerusalem, Research, Rinat Abramovitch, technology, translational medicine, translational research, treatment, Wohl Institute
Cancer / Coronavirus / Covid / Creative / Education / Foundation / Future / General / Genetics / Hadassah / Hadassah Heroes / Hospital / Jerusalem / News / Nonprofit / Relief / Research / Uncategorized
Just six months have passed since the Wohl Institute for Translational Medicine opened at Hadassah Hospital Ein Kerem, but it has already become the focus of 30 research projects from Hadassah.
“In such a short time, with nearly half of it dominated by COVID-19, we’ve established ourselves as a national centre,” says Institute Director Prof. Rinat Abramovitch, Ph.D.
Lone researchers, previously stymied by the unaffordability of sophisticated imaging equipment, can now use the Wohl facilities, made possible by funds from the United Kingdom-based Wohl Legacy, a gift facilitated by Hadassah United Kingdom.
24th October 2019 – from left, HMO Director General Zeev Rotstein,
Legacy Trustees Dr. David Latchman and Ella Latchman, sister of the late Maurice Wohl.
Photo credit to Avi Hayun
Wohl Institute researchers are already publishing in scientific journals. For example, a research team that includes Hadassah nephrologists has an article on microRNA in chronic kidney disease in the Journal of the Federation of European Biochemical Societies. In another example, Emma Hajaj, an MD-PhD candidate at Hadassah’s Sharett Institute of Oncology, published a paper in the medical journal ELife after she and her team found a way to make immunotherapy more successful for melanoma patients.